Soligenix Inc. (NASDAQ:SNGX) Short Interest Up 837.4% in May

Posted by Geri Gentry on Jun 10th, 2026

Soligenix Inc. (NASDAQ:SNGX – Get Free Report) was the target of a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 6,514,042 shares, a growth of 837.4% from the May 14th total of 694,906 shares. Currently, 45.3% of the shares of the stock are short sold. Based on an average trading volume of 42,539,946 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Soligenix has a consensus rating of “Hold” and an average target price of $6.00.

Read Our Latest Stock Report on Soligenix

Institutional Trading of Soligenix

Institutional investors have recently bought and sold shares of the company. StoneX Group Inc. acquired a new stake in Soligenix during the fourth quarter valued at $50,000. Armistice Capital LLC acquired a new stake in Soligenix during the third quarter valued at $821,000. Geode Capital Management LLC boosted its position in Soligenix by 88.8% during the fourth quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 37,811 shares during the last quarter. Two Sigma Investments LP acquired a new stake in Soligenix during the third quarter valued at $102,000. Finally, Virtu Financial LLC acquired a new stake in Soligenix during the third quarter valued at $59,000. Institutional investors and hedge funds own 3.60% of the company’s stock.

Soligenix Trading Up 1.1%

SNGX opened at $0.43 on Wednesday. The stock has a market cap of $6.33 million, a price-to-earnings ratio of -0.25 and a beta of 1.84. Soligenix has a 1 year low of $0.28 and a 1 year high of $6.23. The stock has a fifty day moving average price of $0.78 and a 200 day moving average price of $1.12.

Soligenix (NASDAQ:SNGX – Get Free Report) last released its quarterly earnings data on Friday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. As a group, sell-side analysts forecast that Soligenix will post -0.9 earnings per share for the current fiscal year.

Soligenix Company Profile

(Get Free Report)

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.